Tumour angiogenesis is reduced in the Tc1 mouse model of Down’s syndrome (original) (raw)

Nature volume 465, pages 813–817 (2010)Cite this article

Subjects

A Corrigendum to this article was published on 15 July 2010

Abstract

Down’s syndrome (DS) is a genetic disorder caused by full or partial trisomy of human chromosome 21 and presents with many clinical phenotypes including a reduced incidence of solid tumours1,2. Recent work with the Ts65Dn model of DS, which has orthologues of about 50% of the genes on chromosome 21 (Hsa21), has indicated that three copies of the ETS2 (ref. 3) or DS candidate region 1 (DSCR1) genes4 (a previously known suppressor of angiogenesis5,6) is sufficient to inhibit tumour growth. Here we use the Tc1 transchromosomic mouse model of DS7 to dissect the contribution of extra copies of genes on Hsa21 to tumour angiogenesis. This mouse expresses roughly 81% of Hsa21 genes but not the human DSCR1 region. We transplanted B16F0 and Lewis lung carcinoma tumour cells into Tc1 mice and showed that growth of these tumours was substantially reduced compared with wild-type littermate controls. Furthermore, tumour angiogenesis was significantly repressed in Tc1 mice. In particular, in vitro and in vivo angiogenic responses to vascular endothelial growth factor (VEGF) were inhibited. Examination of the genes on the segment of Hsa21 in Tc1 mice identified putative anti-angiogenic genes (ADAMTS18,9and ERG10) and novel endothelial cell-specific genes11, never previously shown to be involved in angiogenesis (JAM-B12 and PTTG1IP), that, when overexpressed, are responsible for inhibiting angiogenic responses to VEGF. Three copies of these genes within the stromal compartment reduced tumour angiogenesis, explaining the reduced tumour growth in DS. Furthermore, we expect that, in addition to the candidate genes that we show to be involved in the repression of angiogenesis, the Tc1 mouse model of DS will permit the identification of other endothelium-specific anti-angiogenic targets relevant to a broad spectrum of cancer patients.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

References

  1. Yang, Q., Rasmussen, S. A. & Friedman, J. M. Mortality associated with Down’s syndrome in the USA from 1983 to 1997: a population-based study. Lancet 359, 1019–1025 (2002)
    Article PubMed Google Scholar
  2. Hasle, H. Pattern of malignant disorders in individuals with Down’s syndrome. Lancet Oncol. 2, 429–436 (2001)
    Article CAS PubMed Google Scholar
  3. Sussan, T. E., Yang, A., Li, F., Ostrowski, M. C. & Reeves, R. H. Trisomy represses Apc Min -mediated tumours in mouse models of Down’s syndrome. Nature 451, 73–75 (2008)
    Article CAS ADS PubMed Google Scholar
  4. Baek, K. H. et al. Down’s syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 459, 1126–1130 (2009)
    Article CAS ADS PubMed PubMed Central Google Scholar
  5. Iizuka, M., Abe, M., Shiiba, K., Sasaki, I. & Sato, Y. Down syndrome candidate region 1, a downstream target of VEGF, participates in endothelial cell migration and angiogenesis. J. Vasc. Res. 41, 334–344 (2004)
    Article CAS PubMed Google Scholar
  6. Minami, T. et al. Vascular endothelial growth factor- and thrombin-induced termination factor, Down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis. J. Biol. Chem. 279, 50537–50554 (2004)
    Article CAS PubMed Google Scholar
  7. O’Doherty, A. et al. An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science 309, 2033–2037 (2005)
    Article ADS PubMed PubMed Central Google Scholar
  8. Luque, A., Carpizo, D. R. & Iruela-Arispe, M. L. ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. J. Biol. Chem. 278, 23656–23665 (2003)
    Article CAS PubMed Google Scholar
  9. Lee, N. V. et al. ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2. EMBO J. 25, 5270–5283 (2006)
    Article CAS PubMed PubMed Central Google Scholar
  10. Birdsey, G. M. et al. Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood 111, 3498–3506 (2008)
    Article CAS PubMed PubMed Central Google Scholar
  11. Herbert, J. M., Stekel, D., Sanderson, S., Heath, V. L. & Bicknell, R. A novel method of differential gene expression analysis using multiple cDNA libraries applied to the identification of tumour endothelial genes. BMC Genomics 9, 153 (2008)
    Article PubMed PubMed Central Google Scholar
  12. Aurrand-Lions, M., Duncan, L., Ballestrem, C. & Imhof, B. A. JAM-2, a novel immunoglobulin superfamily molecule, expressed by endothelial and lymphatic cells. J. Biol. Chem. 276, 2733–2741 (2001)
    Article CAS PubMed Google Scholar
  13. Holash, J. et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284, 1994–1998 (1999)
    Article CAS PubMed Google Scholar
  14. Williams, B. R. et al. Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. Science 322, 703–709 (2008)
    Article CAS ADS PubMed PubMed Central Google Scholar
  15. Shalaby, F. et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62–66 (1995)
    Article CAS ADS PubMed Google Scholar
  16. Reynolds, A. R. et al. Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in β3-integrin-deficient mice. Cancer Res. 64, 8643–8650 (2004)
    Article CAS PubMed Google Scholar
  17. Kelly, P. A. & Rahmani, Z. DYRK1A enhances the mitogen-activated protein kinase cascade in PC12 cells by forming a complex with Ras, B-Raf, and MEK1. Mol. Biol. Cell 16, 3562–3573 (2005)
    Article CAS PubMed PubMed Central Google Scholar
  18. Gampel, A. et al. VEGF regulates the mobilization of VEGFR2/KDR from an intracellular endothelial storage compartment. Blood 108, 2624–2631 (2006)
    Article CAS PubMed Google Scholar
  19. Lampugnani, M. G., Orsenigo, F., Gagliani, M. C., Tacchetti, C. & Dejana, E. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J. Cell Biol. 174, 593–604 (2006)
    Article CAS PubMed PubMed Central Google Scholar
  20. Wolvetang, E. J. et al. ETS2 overexpression in transgenic models and in Down syndrome predisposes to apoptosis via the p53 pathway. Hum. Mol. Genet. 12, 247–255 (2003)
    Article CAS PubMed Google Scholar
  21. Liu, Y. J., Xu, Y. & Yu, Q. Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively. Oncogene 25, 2452–2467 (2006)
    Article CAS PubMed PubMed Central Google Scholar
  22. Carbone, G. M. et al. Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells. Nucleic Acids Res. 32, 4358–4367 (2004)
    Article CAS PubMed PubMed Central Google Scholar
  23. Yamamoto, H. et al. Defective trophoblast function in mice with a targeted mutation of Ets2. Genes Dev. 12, 1315–1326 (1998)
    Article CAS PubMed PubMed Central Google Scholar
  24. Park, J. S. et al. A role for both Ets and C/EBP transcription factors and mRNA stabilization in the MAPK-dependent increase in p21Cip-1/WAF1/mda6 protein levels in primary hepatocytes. Mol. Biol. Cell 11, 2915–2932 (2000)
    Article CAS PubMed PubMed Central Google Scholar
  25. Shozu, M. et al. ADAMTS-1 is involved in normal follicular development, ovulatory process and organization of the medullary vascular network in the ovary. J. Mol. Endocrinol. 35, 343–355 (2005)
    Article CAS PubMed Google Scholar
  26. Harris, C. D., Ermak, G. & Davies, K. J. Multiple roles of the DSCR1 (Adapt78 or RCAN1) gene and its protein product calcipressin 1 (or RCAN1) in disease. Cell. Mol. Life Sci. 62, 2477–2486 (2005)
    Article CAS PubMed Google Scholar
  27. Reynolds, A. R. et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nature Med. 15, 392–400 (2009)
    Article CAS PubMed Google Scholar
  28. Reynolds, L. E. et al. Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins. Nature Med. 8, 27–34 (2002)
    Article CAS PubMed Google Scholar
  29. Mahadevan, V., Hart, I. R. & Lewis, G. P. Factors influencing blood supply in wound granuloma quantitated by a new in vivo technique. Cancer Res. 49, 415–419 (1989)
    CAS PubMed Google Scholar

Download references

Acknowledgements

We thank G. Saunders, C. Wren, C. Pegrum and A. Slender for their help with animal husbandry; F. Wiseman and T. Broughton for information on gene deletions in the Tc1 mice; and L. Iruela-Arispe for advice on ADAMTS1 mice and antibody gift.

Author information

Author notes

  1. Alan R. Watson and Marianne Baker: These authors contributed equally to this work.

Authors and Affiliations

  1. Adhesion and Angiogenesis Laboratory, Barts Institute of Cancer, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, UK ,
    Louise E. Reynolds, Alan R. Watson, Marianne Baker, Gabriela D’Amico, Stephen D. Robinson & Kairbaan M. Hodivala-Dilke
  2. Centre for Tumour Biology, Institute of Cancer, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, UK ,
    Carine Joffre, Stephanie Kermorgant & Ian R. Hart
  3. Neuroscience Centre, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Institute of Cell and Molecular Sciences, 4 Newark Street, London E1 2AD, UK ,
    Tania A. Jones & Denise Sheer
  4. Paediatrics Centre, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Institute of Cell and Molecular Sciences, 4 Newark Street, London E1 2AD, UK ,
    Dean Nizetic
  5. Department of Pathology and Immunology, Centre Medical Universitaire, University of Geneva Medical School (CMU), rue Michel Servet 1, CH-1211 Geneva, Switzerland,
    Sarah Garrido-Urbani & Beat A. Imhof
  6. GENYO, Avenida Del Conocimiento, s/n Armilla 18100, Granada, Spain ,
    Juan Carlos Rodriguez-Manzaneque & Estefanía Martino-Echarri
  7. INSERM, 27, Boulevard Lei Roure, 13009 Marseille, France ,
    Michel Aurrand-Lions
  8. Human Genetics Institute, Galliere Hospital, Via Volta 10, 16128 Genoa, Italy ,
    Franca Dagna-Bricarelli
  9. School of Clinical and Experimental Medicine, University of Birmingham, Birmingham B15 2TT, UK
    Christopher J. McCabe
  10. School of Cancer Sciences, University of Birmingham, Birmingham B15 2TT, UK
    Andrew S. Turnell
  11. Max Planck Institute for Molecular Biomedicine, Röntgenstrasse 20, D-48149 Münster, Germany ,
    Ralf Adams
  12. Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK,
    Elizabeth M. C. Fisher
  13. Division of Immune Cell Biology, MRC National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, UK,
    Victor L. J. Tybulewicz

Authors

  1. Louise E. Reynolds
  2. Alan R. Watson
  3. Marianne Baker
  4. Tania A. Jones
  5. Gabriela D’Amico
  6. Stephen D. Robinson
  7. Carine Joffre
  8. Sarah Garrido-Urbani
  9. Juan Carlos Rodriguez-Manzaneque
  10. Estefanía Martino-Echarri
  11. Michel Aurrand-Lions
  12. Denise Sheer
  13. Franca Dagna-Bricarelli
  14. Dean Nizetic
  15. Christopher J. McCabe
  16. Andrew S. Turnell
  17. Stephanie Kermorgant
  18. Beat A. Imhof
  19. Ralf Adams
  20. Elizabeth M. C. Fisher
  21. Victor L. J. Tybulewicz
  22. Ian R. Hart
  23. Kairbaan M. Hodivala-Dilke

Contributions

L.E.R. and K.M.H-D. designed the experiments. L.E.R. performed the experiments. A.R.W. performed the bone marrow transplant experiments and stained for Y chromosome and conducted RT–PCR. G.D’A. performed the aortic ring assay. S.D.R. performed the phospho-VEGFR2 western blot analysis. T.A.J. and D.S. performed the tumour cell karyotyping. M.B. assisted with the immunostaining, tumour and sponge harvesting and flow cytometric analysis. C.J. and S.K. conducted flow cytometry and immunofluorescence of cells. B.A.I., R.A. and S.G.-U. supplied the JAM-B antibodies for western blot analysis and JAM-B wild-type and heterozygous mice for in vivo and ex vivo studies and JAM-B biochemistry in JAM-B heterozygotes. J.C.R.-M. and E.M.-E. provided the ADAMTS1 heterozygous aortae and ADAMTS1 PCR analysis. C.J.M. and A.T. provided the PTTG1IP antibody for western blot analysis. F.D.-B. and D.N. provided the human DS and normal control cells. V.J.T. and E.M.C.F. designed , developed and provided the Tc1 mice. L.E.R., K.M.H-D. and I.R.H. wrote the paper with substantial input from the other authors.

Corresponding author

Correspondence toLouise E. Reynolds.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

PowerPoint slides

Rights and permissions

About this article

Cite this article

Reynolds, L., Watson, A., Baker, M. et al. Tumour angiogenesis is reduced in the Tc1 mouse model of Down’s syndrome.Nature 465, 813–817 (2010). https://doi.org/10.1038/nature09106

Download citation

This article is cited by

Comments

Commenting on this article is now closed.

  1. Dongwei Gao 16 June 2010, 23:30
    In this paper , i pay more attention to combination of four genes that can inhibit tumor growth. This study, together with previous study of < Mediators of vascular remodelling co-opted for sequential steps in lung metastasis> may support an idea that combinatorial molecular thearpy is a direction for treatment of cancer and metastasis.

Editorial Summary

Down's syndrome is caused by the presence of an extra copy of chromosome 21 (a state known as trisomy), and it is known that the growth of certain tumours is reduced in this genetic disorder. A study of a mouse model of Down's syndrome points to an antitumour mechanism, the inhibition of tumour angiogenesis by the overexpression of four genes, two putative anti-angiogenic genes (ADAMTS1 and ERG) and two novel endothelial cell-specific genes not previously linked with angiogenesis (JAM-B and PTTG1IP).

Associated content